Orchid Pharma Ltd (NSE: ORCHPHARMA) and Symbiotec Pharmalab (NSE: SYMBIOTEC) are both listed in the Medicinal Chemicals and Botanical Products industry. Orchid Pharma has a market capitalisation of ₹5,074 Cr and Symbiotec Pharmalab ₹7,871 Cr, as of 9 Nov 2026. Their P/E ratios are 510.4 and 64.5 respectively.
| Metric | Orchid Pharma | Symbiotec Pharmalab |
|---|---|---|
| NSE Symbol | ORCHPHARMA | SYMBIOTEC |
| BSE Code | 524372 | 544889 |
| Share Price | ₹884.00 | ₹1,546.20 |
| Market Cap | ₹5,074 Cr | ₹7,871 Cr |
| P/E Ratio | 510.4 | 64.5 |
| Return on Equity | 0.70% | — |
| Return on Assets | 0.12% | 6.96% |
| Beta (1Y) | 0.81 | -3.22 |
| 1-Year Price Change | +14.8% | — |
| 3-Month Price Change | -18.1% | — |
| 52-Week Range | ₹480.00 – ₹1,143.50 | ₹934.20 – ₹1,609.00 |
| Latest Quarter | Q1 FY27 | Q2 FY27 |
| Quarterly Revenue | ₹304 Cr | ₹280 Cr |
| Quarterly Net Profit | ₹3 Cr | ₹52 Cr |
| Net Margin | 1.1% | 18.5% |
| EPS (Basic, Quarter) | ₹0.54 | ₹8.20 |
| Results Basis | consolidated | consolidated |
| Headquarters | Chennai, Tamil Nadu | Indore, Madhya Pradesh |
The figures sit side by side and are not ranked. Quarterly figures are in ₹ crore, parsed from each company's exchange filing (XBRL); the two companies' latest quarters can differ.
Orchid Pharma Limited, a pharmaceutical company, engages in the development, manufacture, and marketing of active pharmaceutical ingredients, bulk actives, finished dosage formulations, and nutraceuticals in India. Its active pharmaceutical ingredients product portfolio includes oral cephalosporins, injectable cephalosporins; human and veterinary products; and antibiotics, including betalactam, macrolide, fluoroquinolone, and imidazole. The company also exports its products to approximately 40 countries internationally. The company was formerly known as Orchid Chemicals & Pharmaceuticals Limit…
Symbiotec Pharma Lab Pvt. Ltd. develops, manufactures, and markets active pharmaceutical ingredients (APIs), with a primary focus on cortico-steroids and steroid-hormone APIs in both sterile and non-sterile forms. The company synthesizes progestin, estrone, testosterone, their derivatives, and anabolic steroids, supplying these in commercial volumes globally. It offers APIs and intermediate pharmaceutical products for therapeutic areas such as gastrointestinal ailments, cardiovascular disease, pain management, paediatrics, anti-infective, and dermatology. The company provides contract manufact…
Symbiotec Pharmalab has a market capitalisation of ₹7,871 Cr, against ₹5,074 Cr for Orchid Pharma as of 9 Nov 2026, about 1.6 times the size by market cap.
Orchid Pharma has a P/E of 510.4 and Symbiotec Pharmalab a P/E of 64.5 as of 9 Nov 2026.
Orchid Pharma reported revenue of ₹304 Cr and net profit of ₹3 Cr for Q1 FY27. Symbiotec Pharmalab reported revenue of ₹280 Cr and net profit of ₹52 Cr for Q2 FY27. Figures are parsed from each company's exchange filing.
Both are classified under Pharmaceuticals > Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products on FinBizNet.
No. The page lays the two companies' published figures side by side and draws no conclusion from them. It is descriptive market data, not investment advice.
Data as of 9 Nov 2026. Descriptive market data only — not investment advice.